We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who cur... Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Show more
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024...
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire AUSTIN, Texas, April 3, 2024...
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System PR Newswire AUSTIN, Texas, April 2, 2024 NPRL2 Gene Therapy Induces Anti-Tumor...
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas, March 22, 2024 AUSTIN, Texas, March 22, 2024 /PRNewswire/...
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas, March 19, 2024 AUSTIN, Texas, March 19, 2024 /PRNewswire/ -- Genprex...
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas, March 19, 2024 AUSTIN, Texas, March 19, 2024 /PRNewswire/ -- Genprex...
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers PR Newswire AUSTIN, Texas, March 12, 2024 Expands on...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.65 | -23.381294964 | 2.78 | 2.8699 | 2.09 | 22410 | 2.35526671 | CS |
4 | -0.87 | -29 | 3 | 3.27 | 2.09 | 43545 | 2.87641187 | CS |
12 | -7.07 | -76.847826087 | 9.2 | 13 | 2.09 | 317953 | 8.14280637 | CS |
26 | -10.67 | -83.359375 | 12.8 | 14.796 | 2.09 | 343422 | 8.94069067 | CS |
52 | -41.87 | -95.1590909091 | 44 | 45.2 | 2.09 | 458445 | 22.88808271 | CS |
156 | -155.47 | -98.6484771574 | 157.6 | 166.4 | 2.09 | 867676 | 98.40327304 | CS |
260 | -69.47 | -97.0251396648 | 71.6 | 308.8 | 2.09 | 1276372 | 117.67804434 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions